Noveris Health Sciences is trading 9.8% down at CA$1.20 as the stock experiences a reversal of recent speculative gains following a period of sharp volatility.
- The move comes despite a lack of new company announcements, regulatory filings, or major news catalysts today.
- The decline appears driven by broader weakness in the biotech sector and a shift toward cautious risk sentiment among investors.
- As a thinly traded micro-cap, the stock remains subject to significant price swings and speculative trading activity.